Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of The Optimal Dosage of Tang Ning Tongluo Capsule for Type II Diabetes

NCT02161276 is registered in ClinicalTrials.gov with Guizhou Bailing Group Pharmaceutical Co Ltd as lead sponsor.

NCT NCT02161276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02161276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of The Optimal Dosage of Tang Ning Tongluo Capsule for Type II Diabetes
Lead sponsor
Guizhou Bailing Group Pharmaceutical Co Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2014
Completion date
September 30, 2014
Enrollment
110 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

accidental exposure while preparing drug for administration